Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1<sup>st</sup> line therapy for adult patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1<sup>st</sup> line therapy for adult patients with diffuse large B-cell lymphoma

Published:2023-03-15 Issue:1 Volume:18 Page:76-87
ISSN:2413-4023
Container-title:Oncohematology
language:
Short-container-title:Onkogematologiâ

Author:

Dyakov I. N.¹^ORCID

Affiliation:

1. Scientific and Practical Center for Rational Pharmacotherapy and Pharmacoeconomics Problems; I.I. Mechnikov Research Institute of Vaccines and Serums

Publisher

Publishing House ABV Press

Subject

Oncology,Hematology

Reference20 articles.

1. State of oncological care in Russia in 2019. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).

2. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16(8):2780–95. DOI:10.1200/JCO.1998.16.8.2780

3. Tilly H., Gomes da Silva M., Vitolo U. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2015; 26(Suppl 5):v116–25. DOI:10.1093/annonc/mdv304

4. Суборцева И.Н. Клинико-биологические особенности первичной экстранодальной диффузной В-крупноклеточной лимфомы. Дис. … канд. мед. наук. М., 2012. Subortseva I.N. Clinical and biological features of primary extranodal diffuse large B-cell lymphoma. Dis. … candidate of medical sciences. Moscow, 2012. (In Russ.).

5. Ziepert M., Hasenclever D., Kuhnt E. et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(14):2373–80. DOI:10.1200/JCO.2009.26.2493